![Pinterest](https://pinterest.com/pin/create/button/?url=https://tech2stop.com/indias-first-indigenous-covid-19-vaccine/&media=https://tech2stop.com/wp-content/uploads/2020/06/tech2stop_12000-_-675-2.jpg&description=Indian Pharmaceutical company "Bharat Biotech'' has announced the development of "COVAXIN", India’s 1st indigenous COVID-19 vaccine.){kind=link}
Indian Pharmaceutical company “Bharat Biotech” has announced the development of “COVAXIN”, India’s 1st indigenous COVID-19 vaccine. This has been done in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune, and transferred to Bharat Biotech. This indigenous vaccine has been developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility zone located in Genome Valley, Hyderabad.
Bharat Biotech stated that the Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare- has granted permission to initiate Phase I & II Human clinical trials after the submission of results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are all set to start across India from July 2020.
Referring to the vaccine development,
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said:
“We are proud to announce COVAXIN™, India’s first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from CDSCO have enabled approvals to this project. Our R&D and manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform.”
The company stated that it accelerated its aim in completing comprehensive pre-clinical studies and also said that the results from these studies have been really promising and show extensive levels of safety and effective immune responses.
“Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic. Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics”
said
Suchitra Ella, joint managing director, Bharat Biotech
Hopefully, this is a great leap in terms of finding a vaccine for the COVID-19 which has taken the world for a spin.
Pay a visit to our Own COVID-CORNER to stay up to date with the latest stats and figures